<DOC>
	<DOCNO>NCT01450280</DOCNO>
	<brief_summary>This open label phase I study , assess safety novel malaria vaccine , AdCh63 CS , simian adenovirus encode Plasmodium falciparum liver stage antigen , Circumsporozoite protein . All volunteer recruit healthy adult . They prim various dos AdCh63 CS administer intramuscularly . Some volunteer receive booster vaccination MVA CS administer via intramuscular route . Safety data collect vaccination regimen . Secondary aim study ass immune response generate vaccination .</brief_summary>
	<brief_title>Safety Immunogenicity New Malaria Vaccine Candidate ChAd63 CS Administered Alone With MVA CS</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<criteria>Inclusion Criteria Healthy adult age 18 50 year Able willing ( Investigator‟s opinion ) comply study requirement Willing allow investigator discuss volunteer‟s medical history General Practitioner Women : Must practice continuous effective contraception duration study Agreement refrain blood donation course study 6 month end involvement study . Written informed consent History clinical P. falciparum malaria Travel malaria endemic region study period within precede six month significant risk malaria exposure . Participation another research study involve investigational product 30 day precede enrolment , plan use study period . Prior receipt investigational malaria vaccine investigational vaccine likely impact interpretation trial data . Administration immunoglobulins and/or blood product within three month precede plan administration vaccine candidate . Any confirm suspected immunosuppressive immunodeficient state , include HIV infection ; asplenia ; recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) Pregnancy , breast feeding intention become pregnant study History allergic disease reaction likely exacerbate component vaccine e.g . egg product , Kathon . History clinically significant contact dermatitis . Any history anaphylaxis post vaccination . History cancer ( except basal cell carcinoma skin cervical carcinoma situ ) . History serious psychiatric condition may affect participation study . Any serious chronic illness require hospital specialist supervision . Suspected known current alcohol abuse define alcohol intake great 42 unit every week . Suspected known inject drug abuse 5 year precede enrolment . Seropositive hepatitis B surface antigen ( HBsAg ) . Seropositive hepatitis C virus ( antibody HCV ) . Any clinically significant abnormal find biochemistry haematology blood test , urinalysis clinical examination . Any significant disease , disorder finding may significantly increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>